Lyka Labs Ltd

Stage 2 · Advancing · week 8Setup 5.0 ★ FairSolid +5.6

As of 16 Oct 2026, Lyka Labs is in Stage 2 — advancing, the uptrend phase, in week 8 (since 26 Aug 2026). It closed at ₹87.79, 10.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. More about the company

₹87.8
+5.00% today
₹317 Cr · Micro cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.0 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #21 of 59 in Pharmaceuticals · #25 of 70 in Health Care

Is LYKALABS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-10.8%
₹45 lo₹98.4 hi
10.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
28.9%
200 DMA: ₹68.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
2.26x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -2.3% vs MA50 +8.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+9.6%
3M
+25.2%
6M
+51.9%
YTD
+14.1%
1Y
-8.1%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #55 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #46 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 16w
S4 43w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 9w → S4 1w → S1 2w → S2 4w → S3 2w → S2 16w → S3 8w → S4 13w → S1 3w → S2 12w → S3 2w → S2 9w → S3 4w → S4 11w → S1 10w → S4 43w → S1 12w → S2 7w current
Total tracked: 167 weeks across 18 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-26
3 appearances in last 60 days. First seen: 2024-08-30.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 8 · Vol 2.26x
2026-10-15S2
Wk 7 · Vol 4.81x
2026-10-14S2
Wk 7 · Vol 4.28x
2026-10-13S2
Wk 7 · Vol 1.95x
2026-10-12S2
Wk 7 · Vol 0.45x
2026-10-09S2
Wk 7 · Vol 1.32x
2026-10-08S2
Wk 6 · Vol 0.57x
2026-10-07S2
Wk 6 · Vol 0.82x
2026-10-06S2
Wk 6 · Vol 2.26x
2026-10-05S2
Wk 6 · Vol 2.02x
2026-10-01S2
Wk 6 · Vol 0.14x
2026-09-30S2
Wk 5 · Vol 1.42x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹77
200 DMA
₹68.1
52W High
₹98.4
52W Low
₹45
5D Low
₹72.2
Resistance levels (recent highs)
20d High
₹87.8
60d High
₹87.8
120d High
₹87.8
250d High
₹98.4
Next resistance
+12.1%
to 250d High
Ask the Market AI about LYKALABSAsk →
About this companyHealth Care· Pharmaceuticals

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.